Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-23.91 Insider Own25.37% Shs Outstand7.35M Perf Week-16.35%
Market Cap4.26M Forward P/E- EPS next Y-2.33 Insider Trans0.00% Shs Float5.48M Perf Month-30.17%
Income-22.50M PEG- EPS next Q-0.47 Inst Own1.60% Short Float5.09% Perf Quarter-46.33%
Sales0.00M P/S- EPS this Y92.08% Inst Trans-73.16% Short Ratio1.24 Perf Half Y-73.89%
Book/sh0.64 P/B0.90 EPS next Y-13.35% ROA-355.56% Short Interest0.28M Perf Year-96.88%
Cash/sh0.15 P/C3.84 EPS next 5Y- ROE-1364.73% 52W Range0.52 - 21.20 Perf YTD-92.42%
Dividend Est.- P/FCF- EPS past 5Y-24.19% ROI-692.54% 52W High-97.27% Beta-0.94
Dividend TTM- Quick Ratio1.21 Sales past 5Y0.00% Gross Margin- 52W Low11.46% ATR (14)0.08
Dividend Ex-Date- Current Ratio1.21 EPS Y/Y TTM18.95% Oper. Margin0.00% RSI (14)30.93 Volatility14.35% 10.65%
Employees13 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price20.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q91.51% Payout- Rel Volume0.77 Prev Close0.62
Sales Surprise- EPS Surprise48.50% Sales Q/Q- EarningsMay 08 BMO Avg Volume224.66K Price0.58
SMA20-18.07% SMA50-28.26% SMA200-87.40% Trades Volume173,225 Change-6.50%
Date Action Analyst Rating Change Price Target Change
Dec-22-23Downgrade Laidlaw Buy → Hold
May-21-24 09:00AM
May-08-24 01:54PM
Apr-30-24 05:45AM
Apr-29-24 09:00AM
05:00PM Loading…
Apr-16-24 05:00PM
Apr-01-24 08:00AM
Mar-19-24 04:45PM
Mar-06-24 06:45AM
Feb-13-24 06:45AM
Feb-06-24 04:15PM
Feb-02-24 09:15AM
Jan-29-24 08:00AM
Dec-28-23 10:15AM
07:00AM Loading…
Dec-06-23 07:00AM
Dec-05-23 07:00AM
Dec-01-23 09:00AM
Nov-13-23 04:15PM
Oct-31-23 07:00AM
Oct-17-23 02:22PM
Sep-21-23 01:30PM
Sep-15-23 07:58AM
Sep-13-23 04:15PM
Sep-11-23 09:22AM
Sep-08-23 04:31PM
Sep-05-23 08:00AM
Aug-14-23 04:15PM
Jul-27-23 06:25AM
08:00AM Loading…
Jul-11-23 08:00AM
Jun-29-23 08:00AM
Jun-14-23 03:45PM
Jun-08-23 07:00AM
May-25-23 03:55PM
May-12-23 03:45PM
May-10-23 04:15PM
May-05-23 11:51AM
May-03-23 06:45AM
Apr-14-23 02:00PM
Apr-04-23 06:45AM
Mar-13-23 06:45AM
Mar-10-23 04:05PM
Feb-24-23 10:19AM
Feb-23-23 04:30PM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
Feb-14-23 06:23AM
Feb-13-23 07:30AM
Jan-09-23 08:25AM
Jan-04-23 06:45AM
Dec-01-22 02:00PM
Nov-30-22 03:00PM
Nov-14-22 06:45AM
Nov-03-22 07:00AM
Nov-01-22 09:02AM
Oct-25-22 07:55AM
Oct-24-22 04:45PM
Oct-20-22 02:20PM
Sep-19-22 06:45AM
Aug-26-22 07:46AM
Aug-15-22 06:34PM
Aug-11-22 06:45AM
Jul-25-22 01:45PM
Jun-23-22 07:00AM
Jun-21-22 08:43AM
Jun-17-22 12:45PM
Jun-02-22 02:40PM
May-24-22 06:45AM
May-19-22 03:15PM
May-18-22 05:20PM
May-12-22 04:15PM
Apr-26-22 12:27PM
Mar-10-22 06:45AM
Feb-15-22 06:45AM
Feb-08-22 12:20PM
Jan-25-22 06:45AM
Dec-13-21 08:45AM
Dec-10-21 11:45AM
Dec-07-21 09:05PM
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Werth Peter J.DirectorApr 11 '24Option Exercise0.001,036,0087531,175,925Apr 12 09:47 PM
Callahan Jennifer L.Corporate ControllerSep 15 '23Buy0.675,0003,34845,508Sep 18 06:00 PM
Werth Peter J.DirectorAug 11 '23Buy0.551,823,1551,000,0012,798,320Aug 14 04:38 PM